Positioning Vascularized Composite Allotransplantation in the Spectrum of Transplantation
Technical Report,15 Sep 2014,14 Sep 2015
Childrens Hospital of Philadelphia Philadelphia United States
Pagination or Media Count:
We have continued our studies of the immune mechanisms contributing to rejection ofvascularized composite allografts VCA in murine models, and how these may be overcome to promote long-term allograft survival. We have now firmly established an orthotopic hind limb VCA model in our lab, and using this orthotopic model, have shown that either of 2 protocols, namely costimulation blockade CD40L monoclonal antibody plus 2 weeks of rapamycin, RPM, or anti-TCR monoclonal antibody plus 2 weeks of RPM, can each achieve long-term VCA survival without maintenance immunosuppression. We are currently using these approaches to explore mechanistic details. Lastly, we have begun to test whether HDAC targeting may have effects on the VCA survival.